Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by American International Group Inc.

American International Group Inc. trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 3.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,701 shares of the company’s stock after selling 1,234 shares during the period. American International Group Inc. owned about 0.10% of Medpace worth $9,717,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of MEDP. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Medpace during the 3rd quarter valued at approximately $1,565,000. Atria Wealth Solutions Inc. lifted its position in shares of Medpace by 11.7% during the 3rd quarter. Atria Wealth Solutions Inc. now owns 4,569 shares of the company’s stock valued at $1,106,000 after acquiring an additional 480 shares during the period. Burney Co. purchased a new position in shares of Medpace during the 3rd quarter worth approximately $205,000. Van ECK Associates Corp increased its stake in shares of Medpace by 42.8% during the 3rd quarter. Van ECK Associates Corp now owns 5,947 shares of the company’s stock worth $1,440,000 after purchasing an additional 1,783 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of Medpace by 14.4% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 1,643 shares of the company’s stock worth $398,000 after purchasing an additional 207 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ashley M. Keating sold 250 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the sale, the director now owns 250 shares of the company’s stock, valued at approximately $102,467.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, VP Susan E. Burwig sold 102 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ashley M. Keating sold 250 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now owns 250 shares in the company, valued at approximately $102,467.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,973 shares of company stock worth $11,960,425. 20.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of recent research reports. Guggenheim raised their price objective on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and lifted their target price for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday. Robert W. Baird lifted their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Moderate Buy” and a consensus target price of $443.14.

Read Our Latest Stock Report on MEDP

Medpace Stock Down 0.5 %

Shares of NASDAQ MEDP opened at $401.19 on Friday. Medpace Holdings, Inc. has a 52-week low of $207.47 and a 52-week high of $421.00. The firm has a fifty day moving average of $393.68 and a 200-day moving average of $354.29. The stock has a market capitalization of $12.43 billion, a PE ratio of 40.90, a P/E/G ratio of 1.98 and a beta of 1.39.

Medpace (NASDAQ:MEDPGet Free Report) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million during the quarter, compared to analysts’ expectations of $512.39 million. During the same period in the previous year, the company earned $2.27 EPS. The business’s quarterly revenue was up 17.7% compared to the same quarter last year. Equities research analysts expect that Medpace Holdings, Inc. will post 11.29 EPS for the current fiscal year.

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Recommended Stories

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.